A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Autor: Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul, Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S.

Publikováno v: In Annals of Oncology February 2022 33(2):181-192